North America Pharmaceutical Excipients Market Analysis and Forecast by Size, Share, Growth, Trends 2034

The North America Pharmaceutical Excipients Market size is expected to reach US$ 8,494.9 Million by 2034 from US$ 4,906.6 Million in 2025. The market is estimated to record a CAGR of 6.4% from 2026 to 2034.

Executive Summary and North America Pharmaceutical Excipients Market Analysis:

The pharmaceutical excipients market in North America is segmented into the US, Canada, and Mexico. The region has an advanced healthcare system, pharmaceutical innovation, and regulatory environment. The pharmaceutical and biotechnology industry in the US and Canada is developing drug formulations that require specialized excipients to improve stability, bioavailability, and patient compliance. The rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer has increased the demand for effective medications, boosting the need for high-quality excipients. Additionally, the growth of generic drugs and biosimilars after patent expirations has expanded production volumes, increasing excipient consumption. Technological advancements in drug delivery systems-such as controlled-release tablets, orally disintegrating tablets, and biologics-also require functional excipients with enhanced performance. Supportive regulatory frameworks from agencies such as the US Food and Drug Administration encourage innovation while maintaining safety standards. Moreover, the presence of major pharmaceutical companies and excipient manufacturers, with investments in research and development, contributes to regional market expansion. Increasing adoption of multifunctional excipients, growth in contract manufacturing organizations, and rising focus on patient-centric drug formulations are also key contributors.

North America Pharmaceutical Excipients Market: Strategic Insights

North America Pharmaceutical Excipients Market Segmentation Analysis:

• By Type, the North America Pharmaceutical Excipients Market is segmented into Bioresorbable Polymers and Lipids and Liposome Based Formulation, Oleochemicals, Sugars, Cellulose, Starches, Petrochemicals, Plant Proteins Polyols and Cyclodextrins, Inorganic Chemicals, and Others. The Cellulose segment dominated the market in 2025.
• By Oleochemicals For Type, the North America Pharmaceutical Excipients Market is segmented into Fatty Alcohols, Metal Stearates, Glycerin, and Other Oleochemicals. The Fatty Alcohols segment dominated the market in 2025.
• By Sugars For Type, the North America Pharmaceutical Excipients Market is segmented into Actual Sugars, Sugar Alcohols, and Artificial Sweeteners. The Actual Sugars segment dominated the market in 2025.
• By Cellulose For Type, the North America Pharmaceutical Excipients Market is segmented into Microcrystalline Cellulose, Cellulose Ethers, and Carboxymethylcellulose and Croscarmellose Sodium. The Microcrystalline Cellulose segment dominated the market in 2025.
• By Starches For Type, the North America Pharmaceutical Excipients Market is segmented into Modified Starches, Dried Starch, and Converted Starch and Pregelatinized Starch. The Modified Starches segment dominated the market in 2025.
• By Petrochemicals For Type, the North America Pharmaceutical Excipients Market is segmented into Glycols, Povidones, Mineral Hydrocarbons, and Other Petrochemicals. The Glycols segment dominated the market in 2025.
• By Inorganic Chemicals For Type, the North America Pharmaceutical Excipients Market is segmented into Magnesium and Calcium Carbonate, Calcium and Aluminum Phosphate, Silicon Dioxide, Titanium Dioxide, and Other Inorganic Chemicals. The Calcium and Aluminum Phosphate segment dominated the market in 2025.
• By Clinical Indication, the North America Pharmaceutical Excipients Market is segmented into Cancer, Metabolic, Infectious Disease, Dental, Ophthalmic, Cardiovascular, and Other Clinical Indications. The Cancer segment dominated the market in 2025.
• By Functionality, the North America Pharmaceutical Excipients Market is segmented into Coloring Agents and Coating Agents, Sweetner and Flavoring Agents, Suspending and Viscosity Agents, Preservative and Controlled Release, Antioxidant and Oil, Tablet Filler and Diluent, Binder and Compression and Granulating Agents, Emulsifiers, Surfactants, and Others. The Tablet Filler and Diluent segment dominated the market in 2025.
• By Surfactants For Functionality, the North America Pharmaceutical Excipients Market is segmented into Polyoxyethylene Hydrogenated Castor Oil, Polysorbates, Sodium Dodecyl Sulfate, and Other Surfactants. The Polysorbates segment dominated the market in 2025.
• By Application, the North America Pharmaceutical Excipients Market is segmented into Oral, Injectable, Topical, and Others. The Oral segment dominated the market in 2025.
• By Oral For Application, the North America Pharmaceutical Excipients Market is segmented into Tablet, Capsule, Liquid, and Others. The Tablet segment dominated the market in 2025.
• By Capsule For Oral, the North America Pharmaceutical Excipients Market is segmented into Hard Gel and Soft Gel. The Hard Gel segment dominated the market in 2025.
• By End User, the North America Pharmaceutical Excipients Market is segmented into Pharma Industries, Biopharma Industries, Animal Health, and Other End User. The Pharma Industries segment dominated the market in 2025.

North America Pharmaceutical Excipients Market Players Density: Understanding Its Impact on Business Dynamics

The North America Pharmaceutical Excipients Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

North America Pharmaceutical Excipients Market Outlook

The pharmaceutical excipients market is experiencing a surge in demand driven by the widespread adoption of generic medications, which account for 90% of all prescriptions filled in the US, according to the US Food and Drug Administration (FDA). Generic drugs are the alternatives to branded drugs with the same dosage form, safety, strength, administration route, and quality. According to the FDA, in the US, ~9 out of 10 prescriptions have generic drugs. Governments of developing countries are focusing on reducing healthcare costs by boosting the production of generic drugs. This shift toward generics, which often replicate the active ingredients of branded drugs but rely heavily on excipients for stability, bioavailability, and manufacturability, has amplified the need for versatile inactive ingredients. Excipients comprise more than 90% of most generic drug formulations and play critical roles in ensuring product equivalence and patient safety, as highlighted by the International Pharmaceutical Excipients Council (IPEC). In the development of generic metformin hydrochloride tablets, variations in excipients such as microcrystalline cellulose and magnesium stearate have been shown to influence tablet hardness, dissolution rates, and quality attributes, underscoring the importance of precise formulation matching to achieve bioequivalence with the reference branded product. This demand extends to advanced formulations, where excipients enable innovative delivery systems, such as amorphous solid dispersions (ASDs), for poorly soluble drugs. In FDA-funded research, hypromellose acetate succinate emerged as a dominant carrier in spray-dried ASDs for generics, increasing drug loading from 5% to 30% with only 5% surfactant, impacting dissolution profiles and bioavailability. Similarly, hydroxypropyl methylcellulose (HPMC) matrices are pivotal in modified-release generics, where design-of-experiments studies revealed that excipient ratios affect scaling across strengths, ensuring consistent in vivo performance under dynamic gastrointestinal conditions. These advancements address complex challenges in generic development, such as food effects and polymorphic stability, fostering competition and accessibility.

Excipients have become an integral element in the manufacturing of tablets as these provide improved functionality in pharmaceuticals and aid in drug development and innovation, which help improve patent life at a lower cost. As generic approvals continue-with 59 first-time generics approved in fiscal year 2024-excipients remain indispensable for mitigating risks and supporting cost-effective therapies, benefiting public health through broader availability of affordable, high-quality medications.

North America Pharmaceutical Excipients Market Country Insights

By country, the North America Pharmaceutical Excipients Market is segmented into United States, Canada, and Mexico. The United States held the largest share in 2025.

In the US, pharmaceutical excipients serve as essential inactive ingredients that enhance drug stability, bioavailability, and patient compliance in treatments for widespread chronic conditions. These substances, ranging from binders and fillers to coatings and preservatives, are integral to oral tablets, injectables, and topical formulations, ensuring safe and effective delivery of active pharmaceuticals amid a growing burden of noncommunicable diseases. According to the Centers for Disease Control and Prevention (CDC), an estimated 129 million Americans, or ~40% of the adult population, live with at least one major chronic disease, including heart disease, cancer, diabetes, obesity, and hypertension. In 2023, heart disease remained the leading cause of death with 680,909 fatalities, followed by cancer at 613,331 deaths, and diabetes contributing to over 100,000 deaths annually as a key comorbidity. Additionally, 76.4% of adults, representing 194 million people, reported one or more chronic conditions in 2023, underscoring the demand for reliable excipient-based therapies to manage these prevalent issues. This landscape drives ongoing innovation and regulatory oversight to maintain excipient quality.

Recent developments highlight the US Food and Drug Administration's (FDA) emphasis on supply chain integrity; in February 2026, the agency issued guidance urging compounders to rigorously verify bulk drug substances and excipient suppliers to mitigate contamination risks. Complementing this, the FDA launched the PreCheck program in August 2025 to bolster domestic pharmaceutical manufacturing, facilitating faster inspections and approvals for excipient producers. In 2024, the FDA approved 50 novel drugs, incorporating advanced excipients such as novel polymers for controlled release and lipid-based carriers for improved solubility in diabetes and cardiovascular treatments. Furthermore, the February 2024 update to the Handbook of Pharmaceutical Excipients added one new monograph and revised 17 others, reflecting harmonized pharmacopeial standards for safety and efficacy. These advancements align with current Good Manufacturing Practice (cGMP) regulations, ensuring excipients meet stringent purity and functionality requirements. As chronic disease prevalence rises, particularly among aging populations, such regulatory and innovative efforts continue to support accessible, high-quality medications, reducing formulation challenges and enhancing therapeutic outcomes across the healthcare spectrum.

North America Pharmaceutical Excipients Market Company Profiles

Some of the key players operating in the market include BASF SE, JRS PHARMA GmbH & Co KG, Roquette Freres SA, Avantor Inc, Archer-Daniels-Midland Co, Evonik Industries AG, Merck KGaA, The Dow Chemical Co, The Lubrizol Corp, Ashland Inc, and MEGGLE GmbH & Co KG.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

North America Pharmaceutical Excipients Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise